odiparcil has been researched along with ARSB Deficiency in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abitbol, JL; Chowdary, P; Faudot-Vernier, E; Fiquet, A; Guffon, N; Hendriksz, CJ; Hennermann, JB; Hughes, D; Huot-Marchand, P; Lacombe, O; Richard, MP; Tallandier, M; Teles, EL | 1 |
| Bocart, S; Bouchot, A; Bournique, B; Broqua, P; Entchev, E; Jantzen, I; Junien, JL; Lacombe, O; Luccarini, JM; Masson, P; Tallandier, M | 1 |
| Antonelli, S; Cimbolini, N; Entchev, E; Feraille, L; Germain, JM; Jantzen, I; Lacombe, O; Luccarrini, JM; Mauro, V; Roussey, A; Tallandier, M; Young, SP; Zhang, H | 1 |
1 trial(s) available for odiparcil and ARSB Deficiency
| Article | Year |
|---|---|
Oral treatment for mucopolysaccharidosis VI: Outcomes of the first phase IIa study with odiparcil.
Topics: Enzyme Replacement Therapy; Glycosaminoglycans; Glycosides; Humans; Mucopolysaccharidoses; Mucopolysaccharidosis VI; N-Acetylgalactosamine-4-Sulfatase | 2022 |
2 other study(ies) available for odiparcil and ARSB Deficiency
| Article | Year |
|---|---|
Odiparcil, a potential glycosaminoglycans clearance therapy in mucopolysaccharidosis VI-Evidence from in vitro and in vivo models.
Topics: Administration, Oral; Animals; Cattle; Cells, Cultured; Chondroitin Sulfates; Dermatan Sulfate; Disease Models, Animal; Endothelial Cells; Female; Glycosaminoglycans; Glycosides; Humans; In Vitro Techniques; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Mucopolysaccharidosis VI; Rats; Rats, Sprague-Dawley | 2020 |
MPS VI associated ocular phenotypes in an MPS VI murine model and the therapeutic effects of odiparcil treatment.
Topics: Animals; Disease Models, Animal; Eye; Eye Diseases; Glycosides; Humans; Mice; Mucopolysaccharidosis VI; N-Acetylgalactosamine-4-Sulfatase; Phenotype | 2022 |